Targeted Antibiotic Delivery: Selective Siderophore Conjugation with Daptomycin Confers Potent Activity against Multidrug Resistant Acinetobacter baumannii Both in Vitro and in Vivo

被引:112
作者
Ghosh, Manuka [1 ]
Miller, Patricia A. [1 ,2 ]
Mollmann, Ute [1 ]
Claypoo, William D. [3 ]
Schroeder, Valerie A. [4 ]
Wolter, William R. [4 ]
Suckow, Mark [4 ]
Yu, Honglin [5 ]
Li, Shuang [5 ]
Huang, Weigiang [5 ]
Zajicek, Jaroslav [2 ]
Miller, Marvin J. [1 ,2 ]
机构
[1] Hsiri Therapeut, Innovat Pk,1400 East Angela Blvd, South Bend, IN 46617 USA
[2] Univ Notre Dame, Dept Chem & Biochem, Notre Dame, IN 46556 USA
[3] Hsiri Therapeut LLC, Rosetree Corp Ctr, 1400 N Providence Rd,Bldg 1,Suite 115S, Media, PA 19063 USA
[4] Univ Notre Dame, Frieman Life Sci Ctr, Notre Dame, IN 46556 USA
[5] PracticaChem, 5 Lanyuan Rd,Room D-603,Huayuan Ind Pk, Tianjin 300384, Peoples R China
关键词
GRAM-POSITIVE INFECTIONS; ANTIBACTERIAL ACTIVITY; ESCHERICHIA-COLI; IRON TRANSPORT; AGENTS; DISCOVERY; ALBOMYCIN;
D O I
10.1021/acs.jmedchem.7b00102
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
In order to address the dire need for new antibiotics to treat specific strains of drug resistant Gram-negative bacterial infections, a mixed ligand analog of the natural Acinetobacter baumannii selective siderophore, fimsbactin, was coupled to daptomycin, a Gram-positive only antibiotic. The resulting conjugate 11 has potent activity against multidrug resistant strains of A. baumannii both in vitro and in vivo. The study also indicates that conjugation of siderophores to "drugs" that are much larger than the siderophore (iron transport agent) itself facilitates active uptake that circumvents the normal permeability problems in Gram-negative bacteria. The results demonstrate the ability to extend activity of a normally Gram-positive only antibiotic to create a potent and targeted Gram-negative antibiotic using a bacterial iron transport based sideromycin Trojan horse strategy.
引用
收藏
页码:4577 / 4583
页数:7
相关论文
共 32 条
[1]   CONSTITUTION OF THE DEFERRIFORM OF THE ALBOMYCINS DELTA-1, DELTA-2, AND EPSILON [J].
BENZ, G ;
SCHRODER, T ;
KURZ, J ;
WUNSCHE, C ;
KARL, W ;
STEFFENS, G ;
PFITZNER, J ;
SCHMIDT, D .
ANGEWANDTE CHEMIE-INTERNATIONAL EDITION IN ENGLISH, 1982, 21 (07) :527-528
[2]   Sideromycins: tools and antibiotics [J].
Braun, Volkmar ;
Pramanik, Avijit ;
Gwinner, Thomas ;
Koeberle, Martin ;
Bohn, Erwin .
BIOMETALS, 2009, 22 (01) :3-13
[3]   Linezolid (ZYVOX), the first member of a completely new class of antibacterial agents for treatment of serious gram-positive infections [J].
Brickner, Steven J. ;
Barbachyn, Michael R. ;
Hutchinson, Douglas K. ;
Manninen, Peter R. .
JOURNAL OF MEDICINAL CHEMISTRY, 2008, 51 (07) :1981-1990
[4]   Antibiotic resistance breakers: can repurposed drugs fill the antibiotic discovery void? [J].
Brown, David .
NATURE REVIEWS DRUG DISCOVERY, 2015, 14 (12) :821-832
[5]   Investigational Agents for the Treatment of Gram-Negative Bacterial Infections: A Reality Check [J].
Bush, Karen .
ACS INFECTIOUS DISEASES, 2015, 1 (11) :509-511
[6]   Total synthesis of desferrisalmycin B [J].
Dong, L ;
Roosenberg, JM ;
Miller, MJ .
JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, 2002, 124 (50) :15001-15005
[7]   Siderophore-mediated iron transport: Crystal structure of FhuA with bound lipopolysaccharide [J].
Ferguson, AD ;
Hofmann, E ;
Coulton, JW ;
Diederichs, K ;
Welte, W .
SCIENCE, 1998, 282 (5397) :2215-2220
[8]   Endless resistance. Endless antibiotics? [J].
Fisher, Jed F. ;
Mobashery, Shahriar .
MEDCHEMCOMM, 2016, 7 (01) :37-49
[9]   Antibiotic Resistance themed issue [J].
Garneau-Tsodikova, Sylvie ;
Wright, Gerard D. .
MEDCHEMCOMM, 2016, 7 (01) :10-10
[10]   RECENT STUDIES ON ALBOMYCIN, A NEW ANTIBIOTIC [J].
GAUSE, GF .
BRITISH MEDICAL JOURNAL, 1955, 2 (NOV12) :1177-1179